JPH0729935B2 - Cell activator - Google Patents
Cell activatorInfo
- Publication number
- JPH0729935B2 JPH0729935B2 JP60080324A JP8032485A JPH0729935B2 JP H0729935 B2 JPH0729935 B2 JP H0729935B2 JP 60080324 A JP60080324 A JP 60080324A JP 8032485 A JP8032485 A JP 8032485A JP H0729935 B2 JPH0729935 B2 JP H0729935B2
- Authority
- JP
- Japan
- Prior art keywords
- activating agent
- cell activating
- present
- semen
- side effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【発明の詳細な説明】 産業上の利用分野 本発明は、細胞の矢活や老化に起因する疾患の治療用と
して有効な新規細胞賦活剤に関するものである。さらに
詳しくいえば、本発明は、DNA供給源としてヒトから排
泄された精液を用いることにより、なんら副作用を伴う
ことなく、アルツハイマー病、脳血管障害（脳栓塞、脳
梗塞）、心臓病、白内障などのいわゆる老人病に対し著
効を示す細胞賦活剤に関するものである。TECHNICAL FIELD The present invention relates to a novel cell activating agent which is effective for treating diseases caused by cell activation and aging. More specifically, the present invention uses Alzheimer's disease, cerebrovascular disease (cerebral embolism, cerebral infarction), heart disease, cataract, etc. without any side effects by using semen excreted from human as a DNA source. The present invention relates to a cell activator having a remarkable effect on so-called senile diseases.
従来の技術 矢活した細胞に新らしいDNAを導入すると賦活されるこ
とは知られており、この現象を利用して、これまでサ
ル、ウシ、ブタなどの動物の脳、臓器、こう丸などから
抽出された細胞を主成分とした多数の細胞賦活剤が提案
されている。It is known that when a new DNA is introduced into activated cells, it is activated, and by utilizing this phenomenon, the brain, organs, testicles, etc. of animals such as monkeys, cows and pigs have been utilized so far. A large number of cell activators containing extracted cells as a main component have been proposed.
しかしながら、人体を構成する細胞は、多種器官ごとに
多種多様であり、これらの外部から導入されたDNAに対
する挙動もまちまちであるため、上記の細胞賦活剤の作
用は特異的なもので、全ての器官に対し有効とはなり得
ない上に、有効な場合でもその賦活は不完全で、所定の
疾患の治癒が完全に行われるとは限らない。However, the cells that make up the human body are diverse for each type of organ, and the behavior of these externally introduced DNAs is also different. Therefore, the action of the above-described cell activating agent is specific, and It cannot be effective for organs, and even if it is effective, its activation is incomplete, and the cure of a given disease is not always completely achieved.
しかも、これらの細胞賦活剤は、異種動物の細胞を用い
るため、人体内においての親和性を欠き、ある程度の副
作用を伴うのを免れない。Moreover, since these cells activators use cells of different animals, they lack affinity in the human body and are unavoidable with some side effects.
したがって、これまで臨床治療の分野、特に老人治療の
分野においては、人体の各器官に普遍的に作用し、かつ
副作用を伴わない細胞賦活剤の出現が要望されていた。Therefore, in the field of clinical treatment, particularly in the field of geriatric treatment, there has been a demand for the emergence of a cell activating agent that universally acts on each organ of the human body and is free from side effects.
発明が解決しようとする問題点 本発明の目的は、人体内のあらゆる器官における矢活又
は老化した細胞を迅速に賦活することができ、これまで
治癒困難であつた各種の老人病の治療に著効を奏し、し
かも副作用を全く示さない新規な細胞賦活剤を提供する
ことである。Problems to be Solved by the Invention The object of the present invention is to treat various kinds of geriatric diseases that have been difficult to cure until now because they can rapidly activate arrow-activated or aged cells in all organs in the human body. It is an object of the present invention to provide a novel cell activating agent that is effective and has no side effects.
問題点を解決するための手段 本発明者は、各種の老人病に対し有効で、副作用を示さ
ない細胞賦活剤を開発するために、種々研究を重ねた結
果、精子が卵子とともに人体の全ての器官細胞の原点で
あること、精液にはA,AB,B及びＯ型の血液型があるにも
かかわらず、血液の場合と異なり、異種のものを人体内
に導入しても拒絶反応を示さないことに着目し、DNAの
供給源として有精子精液を用いて製剤化したものにより
その目的を達成しうることを見出し、その知見に基づい
て本発明をなすに至つた。Means for Solving the Problems The present inventor has conducted various studies in order to develop a cell activating agent that is effective against various senile diseases and does not show side effects, and as a result, sperm and ovum of all human body Despite being the origin of organ cells, and sperm having A, AB, B, and O blood groups, unlike the case of blood, a rejection reaction occurs even when a foreign substance is introduced into the human body. Focusing on the fact that there is no such thing, it was found that the object can be achieved by the one prepared by using sperm semen as a source of DNA, and the present invention was completed based on the finding.
すなわち、本発明は、ヒトの有精子精液を有効成分とす
る非径口用細胞賦活剤を提供するものであり、減数分裂
した人間のDNAを使用する点に特徴を有する。That is, the present invention provides a non-oral cell activator containing human sperm semen as an active ingredient, and is characterized in that meiotic human DNA is used.
本発明で有効成分として用いる有精子精液は、ヒトの健
康な男子から無菌条件下で採取したものが用いられる。
この場合、細胞活動が最も活発な10代後半から30代前半
の若年者から採取したものが特に好ましい。The spermatozoa semen used as an active ingredient in the present invention is obtained from a healthy male human under sterile conditions.
In this case, those collected from young people in their late teens to early thirties, in which cell activity is most active, are particularly preferable.
このようにして採取された正常な精液中には、６×107
個/cc〜１×108個/ccの精子が含まれている。In normal semen collected in this way, 6 × 10 7
Each sperm is contained in 1 / cc to 1 × 10 8 sperm / cc.
この精液は、生理的食塩水又はグリセリン水溶液で10〜
20倍に希釈して用いられる。この精液は、採取後可及的
速やかに使用することが望ましいが、現実には必要時に
直ちに入手することは困難な場合が多いので、あらかじ
め１回の投与量ごとにアンプル又はカプセルに詰めたも
のを液体窒素中に浸して保存しておくのがよい。このも
のの１回の投与量は、精液基準で0.1〜0.5mlであり、こ
れを１〜７日に１回の割合で非径口的手段で投与する。This semen should be treated with physiological saline or glycerin solution at 10 ~
It is used after diluting 20 times. It is desirable to use this semen as soon as possible after collection, but in reality, it is often difficult to obtain it immediately when necessary, so it should be packaged in ampoules or capsules for each dose in advance. It is advisable to soak them in liquid nitrogen for storage. A single dose of this product is 0.1 to 0.5 ml on the basis of semen, and this is administered once a day from 1 to 7 days by non-oral means.
本発明の細胞賦活剤は、非径口的に投与することが必要
であり、径口的投与ではなんら効果を奏しない。The cell activating agent of the present invention needs to be administered non-orally, and oral administration has no effect.
非径口的投与は、通常皮下注射又は筋肉内注射によつて
行われるが、緊急の場合には静脈内注射で行うこともで
きる。Non-oral administration is usually performed by subcutaneous injection or intramuscular injection, but in an emergency, intravenous injection can also be performed.
本発明の細胞賦活剤は、軽症患者では、１〜２回の投与
で効果が認められ、重症患者でも４〜10回程度で症状の
明らかな改善が認められる。しかも、３か年にわたり11
0回皮下又は筋肉内注射した場合も全く副作用は認めら
れず安全に使用しうることが確かめられている。The cell activating agent of the present invention is effective when administered once or twice in mild patients, and even in severe patients, a clear improvement in symptoms is observed after about 4 to 10 times. And 11 over three years
It has been confirmed that it can be used safely without any side effects even when it is injected subcutaneously or intramuscularly 0 times.
発明の効果 本発明の細胞賦活剤は、アルツハイマー病、脳栓塞及び
脳梗塞後遺症、脳出血後遺症に基づく諸症状例えばめま
い、頭痛、頭重、四肢の麻ひ及びしびれ感などを軽減
し、前立腺肥大症、老人性痴呆症、老人性眼痛、老人性
飛蚊症（白内障）、軽度の脳出血に対し優れた治療効果
を奏し、かつ脳出血の予防にも有効である上に、副作用
は全く認められなかつた。したがつて、各種老人病の治
療薬として好適である。Effect of the Invention The cell activating agent of the present invention reduces Alzheimer's disease, cerebral embolism and cerebral infarction sequelae, various symptoms based on sequelae of cerebral hemorrhage, such as dizziness, headache, head weight, paralysis of extremities and numbness, and prostatic hypertrophy, elderly people. It showed excellent therapeutic effects on senile dementia, senile ocular pain, senile fly mosquito (cataract), and mild cerebral hemorrhage, and was effective in preventing cerebral hemorrhage, and no side effects were observed. Therefore, it is suitable as a therapeutic drug for various geriatric diseases.
実施例 次に実施例により本発明をさらに詳細に説明する。EXAMPLES Next, the present invention will be described in more detail with reference to examples.
実施例１ 健康な青年男子（20才）から、無菌条件下で採取した精
液薬3mlを20分間放置後、グリセリンの10％水溶液40ml
で希釈し、18等分して18個のプラスチツクカプセルに詰
め細胞賦活剤を調製した。Example 1 3 ml of semen drug collected under aseptic conditions from a healthy young boy (20 years old) was allowed to stand for 20 minutes, and then 40 ml of a 10% aqueous solution of glycerin was used.
And diluted into 18 equal parts and packed in 18 plastic capsules to prepare a cell activating agent.
このようにして調製した細胞賦活剤を、各種老人病患者
41人に皮下注射又は筋肉内注射により１日１回投与し、
経過を観察した。その結果を次表に示す。The cell activating agent prepared in this manner was used in various elderly patients.
Administered to 41 people subcutaneously or intramuscularly once a day,
The progress was observed. The results are shown in the table below.
なお、各患者について血液、肝機能、賢機、心電図の検
査を行い、副作用の有無を調べたが、副作用は全く認め
られなかつた。In addition, each patient was examined for blood, liver function, smart device, and electrocardiogram to check for side effects, but no side effects were observed.
Claims (2)
用細胞賦活剤。1. A cell activating agent for non-oral cavity, which comprises human sperm semen as an active ingredient.
１項記載の細胞賦活剤。2. The cell activating agent according to claim 1, which is formulated as an injectable drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60080324A JPH0729935B2 (en) | 1985-04-17 | 1985-04-17 | Cell activator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60080324A JPH0729935B2 (en) | 1985-04-17 | 1985-04-17 | Cell activator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61238726A JPS61238726A (en) | 1986-10-24 |
| JPH0729935B2 true JPH0729935B2 (en) | 1995-04-05 |
Family
ID=13715076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60080324A Expired - Lifetime JPH0729935B2 (en) | 1985-04-17 | 1985-04-17 | Cell activator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0729935B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0692312B2 (en) * | 1989-02-01 | 1994-11-16 | 株式会社赤羽精銀研究所 | Method for producing cell activator |
| JPH0692313B2 (en) * | 1989-10-17 | 1994-11-16 | 株式会社赤羽精銀研究所 | Method for producing cell activator |
-
1985
- 1985-04-17 JP JP60080324A patent/JPH0729935B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61238726A (en) | 1986-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210244771A1 (en) | Methods and materials for treating nerve injuries and neurological disorders | |
| AU2014217942A1 (en) | Compositions and methods for pain relief without numbness | |
| McCabe et al. | Drug effects on postlabyrinthectomy nystagmus | |
| Gumpel et al. | Synoviorthesis with erbium-169: a double-blind controlled comparison of erbium-169 with corticosteroid. | |
| EP3107551B1 (en) | Compositions comprising bicarbonate and calcium salts for pain relief without numbness | |
| DE69835591T2 (en) | INDUCTORS FOR IMMUNOL TOLERANCE | |
| JPH0729935B2 (en) | Cell activator | |
| Hyman et al. | Combination therapy of retinoblastoma with triethylene melamine and radiotherapy | |
| AR006202A1 (en) | USES OF IGE ANTAGONIST TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF ALLERGIC DISEASES AND COMPOSITIONS CONTAINING THEM | |
| FULLER | Use of slowly absorbed suspension of d-tubocurarine chloride in traumatic injury | |
| BAKER et al. | Acute osteomyelitis with staphylococcemia: a clinical report on the use of antitoxin in its treatment | |
| Kadzielawa et al. | Electroencephalographic analysis of the central action of dihydroxyphenylalanine | |
| Wiranowska et al. | A mouse model for the study of blood-brain barrier permeability | |
| Straus | Studies on Antireticular Cytotoxic Serum: I. Introduction and Review of the Literature | |
| RU2129427C1 (en) | Method for treating central nerve system diseases | |
| RU2089197C1 (en) | Preparation exhibiting the prolonged effect and a method of its preparing | |
| Katz et al. | The use of topical thiabendazole in dimethylsulfoxide for creeping eruption: preliminary report | |
| RU2065743C1 (en) | Method for prophylaxis and treatment of endometritis in cows | |
| JPH0729936B2 (en) | Method for producing cell activator | |
| RU2212233C2 (en) | Method for treating some postpartum diseases in animals like cows | |
| James | Collapsed intervertebral discs following lumbar puncture | |
| RU2063774C1 (en) | Method for treating the cases of chronic blood circulation disorders | |
| JPH0692312B2 (en) | Method for producing cell activator | |
| Coates | INTERESTING CASES. | |
| JPH06199678A (en) | Oxytocic action inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |